GlobeNewsWire
14 Oct 2025, 12:45 UTC · 50w ago
Verdict
Headline takes no side. We score CELU +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
PDA-002 achieved a 38.5% wound closure rate in the PAD subgroup versus 22.6% for placebo, demonstrating statistically meaningful efficacy in a condition with zero FDA-approved therapies.
So whatEfficacy in an indication with a $9B annual burden and no approved treatments positions the asset as a high-value commercial opportunity if successfully advanced to approval.
More positive than 99% of claims this week
Celularity stated these Phase 2 findings position the company for a confirmatory Phase 3 trial for DFU/PAD patients.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 98% of claims this week
PDA-002 demonstrated a favorable safety profile with no serious side effects linked to the treatment, remaining consistent through two years of follow-up.
More positive than 87% of claims this week
Celularity is assessing opportunities to offer PDA-002 in Florida under a new state law authorizing the use of stem cell therapies not yet approved by the FDA.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company announced positive Phase 2 clinical trial results demonstrating safety and efficacy for its PDA-002 therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
9h ago
−21.6%
Price is moving against the score
$1.60 vs $2.04 close before publication (Oct 13) · not market-adjusted
CELU chart →
